These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 29885945)

  • 1. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
    Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N
    J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.
    Gilden DM; Kubisiak JM; Pohl GM; Ball DE; Gilden DE; John WJ; Wetmore S; Winfree KB
    J Med Econ; 2017 Feb; 20(2):151-161. PubMed ID: 27574722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
    Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
    Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
    Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
    Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
    Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
    Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Gray SW; Chen AB; Weeks JC; Schrag D
    JAMA; 2012 Apr; 307(15):1593-601. PubMed ID: 22511687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.
    Brooks GA; Austin AM; Uno H; Dragnev KH; Tosteson ANA; Schrag D
    JAMA Netw Open; 2018 Oct; 1(6):e183023. PubMed ID: 30646220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
    Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
    Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
    Ramsey SD; Howlader N; Etzioni RD; Donato B
    J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.
    Lang K; Marciniak MD; Faries D; Stokes M; Buesching D; Earle C; Treat J; Babineaux S; Morissette N; Thompson D
    Value Health; 2009 Jun; 12(4):481-8. PubMed ID: 18980633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
    Velcheti V; Hu X; Piperdi B; Burke T
    Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Bagley SJ; Talento S; Mitra N; Meropol NJ; Cohen RB; Langer CJ; Vachani A
    J Natl Compr Canc Netw; 2019 May; 17(5):469-477. PubMed ID: 31085759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.